FDA Faces Internal Changes and Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Faces Internal Changes and Challenges
Food-safety, transparency, and counterfeit-drug growth will tax agency resources.


Pharmaceutical Technology
Volume 35, Issue 2, pp. 26-30

More transparency

One of Sharfstein's last activities at FDA was to unveil the third phase of the agency's transparency initiative, a program he headed as chair of the agency's Transparency Task Force. Launched in June 2009, the initiative first created an FDA Basics webpage that presents general information on agency operations and public health policies. Next came an FDA-TRACK program to provide the public with measures of the performance and accomplishments of agency offices and regulatory activities.

This latest segment of the project aims to provide regulated companies with useful information on FDA policies and procedures. Some of this will be on the agency's newly launched FDA Industy Basics webpage. In addition, FDA intends to post more information on key staffers and meeting presentations, provide a system to answer industry questions quickly, and clarify agency review processes as well as its system for developing new guidances and regulations. FDA also seeks comments on several draft proposals that are more complex and difficult, such as whether to set specific timelines for guidance development and how to handle sponsor requests to appeal agency decisions.

More significant for industry is FDA's rejection of two other transparency initiative proposals. The agency decided it will not issue binding advisory opinions on the legality of certain marketing and information practices by companies, as sought by industry, similar to practices of the HHS inspector general and the Federal Trade Commission. FDA says that, instead, it will continue to provide advice on whether promotional pieces for drugs meet regulatory standards prior to dissemination, but retain the right to change its opinion later on. Issuing binding advisory opinions "may place inappropriate restrictions on FDA's ability to respond to emerging issues to best protect and promote the public health," the agency stated in its January 2011 report, "Improving Transparency to Regulated Industry."

FDA also will not commit to notifying companies before publicly disclosing information about the safety of a regulated product. The agency will try to discuss emerging quality problems with the manufacturer, and the Center for Drug Evaluation and Research (CDER) will aim to notify sponsors at least 24 hours in advance of plans to post drug-safety information. However, FDA may post information about a safety issue before consulting with the manufacturer if it feels it is necessary to do so to protect public health.

Sharfstein is leaving FDA without resolving the most contentious disclosure proposals issued in its phase-two transparency report, which was issued in May 2010 (see Pharmaceutical Technology's July 2010 Washington Report column). Specifically, the transparency task force continues to evaluate dozens of comments on whether FDA should make public a broad range of confidential regulatory information, such as when a manufacturer files an investigational application and whether such an application is put on hold, withdrawn, or terminated. A key issue is whether to disclose when a company submits a market application for a new drug, biologic, generic drug or medical device, or when that application is withdrawn or abandoned by the sponsor at a later date. Also in question is whether the agency should make public refuse-to-file or complete response letters. FDA is considering expanded disclosure of information from adverse-event reports, evaluations of imports, plant inspection reports, and product recalls as well.

These issues raise "very interesting legal issues" as well as additional resource requirements, Sharfstein explained at his last FDA media briefing. Agency teams are assessing multiple comments on these proposals, and the review is "on track," but resolution is not expected anytime soon.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here